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abnormality in DCS. Although the
function of the CLE is still unclear, a
role as a necessary scaffold for the
lamellar bilayer organization is likely
(Uchida and Holleran, 2008). Thus, CLE
deficiency, coupled with disorganization
of extracellular lamellar bilayers, likely
merge to provoke the barrier abnor-
mality in NLSDI (see Supplementary
Figure S2 online). Finally, to overcome
this metabolic disadvantage in forming
the epidermal permeability barrier, epi-
dermal proliferation likely increases,
which in turn results in hyperkeratosis,
phenotypic features common to virtually
all of the ichthyoses (Demerjian et al.,
2006; Akiyama et al., 2008), that is, ‘A
compromised permeability barrier ‘drives’
the hyperproliferative epidermis in NLSDI
and other ichthyoses’ (Elias et al., 2008).
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TO THE EDITOR
The risk of developing human papillo-
mavirus (HPV)-related benign and
malignant cutaneous lesions is mark-
edly increased in immunosuppressed
people such as organ-transplant recipi-
ents (Harwood et al., 2000) and HIV-
infected patients (Grulich et al., 2007;
Stier and Baranoski, 2008). Although
HPV DNA in plucked eyebrow hair has
been well investigated (Boxman et al.,
1997) in renal transplant recipients and
immunocompetent patients (ICPs) and
correlated with both benign and malig-
nant cutaneous lesions (Struijk et al.,
2003; Plasmeijer et al., 2009), very little
is known about HPV prevalence in
eyebrow hair from HIV patients.
The study design was approved by
the research ethics committee and allAbbreviations: HPV, human papillomavirus; ICP, immunocompetent patient
www.jidonline.org 2499
C Biver-Dalle et al.
HPV DNA in HIV-Infected Patients
patients provided written informed con-
sent before enrollment. The study ad-
hered to the Declaration of Helsinki
Principles. A total of 63 HIV patients
(7 women and 56 men) along with
50 ICPs recruited from the staff of
the medical school and matched by
age and sex were included. Clinical
(medical history, CDC (Centers for
Disease Control and Prevention) sta-
ging, and treatment), immunological
(CD4 cell count), and virological
(HIV viral load) characteristics were
collected. Approximately 10 eyebrow
hair with follicles were plucked using a
sterile pair of tweezers and gloves for
each individual.
HPV detection was performed using
two highly sensitive and specific assays
combining a specific multiplex PCR
with DNA microarray primer extension
as described previously (Gheit et al.,
2007). In brief, for each sample, three
multiplex PCR reactions were per-
formed for the amplification of a-HPV,
b-HPV, and g-HPV types, respectively.
The assays were combined in one
single chip to detect 19 mucosal high-
risk and potential high-risk HPV types
from genus a, 18 low-risk a-HPV types,
25 cutaneous HPV types from genus b,
and 6 cutaneous HPV types from genus
g (Ruer et al., 2009).
For statistical tests, two-sided
hypotheses were used and the statistical
significance was fixed at 5%. The link
between qualitative variables was
assessed using w2 test or Fisher’s exact
test according to the distribution of the
data, and results were presented in
the form of odds ratios with their 95%
confidence intervals.
In all, 63 HIV patients were enrolled
at different CDC stages. The mean CD4
cell count was 568±265 per mm3
with 46% (29/63) of subjects with
o500 CD4 cellmm–3. The mean viral
load was 702±1,996 copiesml–1. In
all, 87% (55/63) of HIV patients were
treated by antiretroviral therapies. The
medical history associated with HPV
infection included genital warts
(27%, 17/63), cutaneous warts (1.6%,
1/63), and cervical dysplasia (3.2%,
2/63). No HIV patient was affected by
skin cancer. Two ICPs had a history
of melanoma, and 4 presented with
cutaneous warts.
We detected HPV DNA in eyebrow
hair of 92 individuals (81%), i.e., 54
HIV patients (86%) and 38 ICPs (76%;
Table 1). The mean number of different
HPV types was significantly higher in
HIV patients (n¼ 4.5) than in ICPs (n¼ 3,
Po0.05). We did not observe any age
trend in the number of HPV types per
individual in the two study groups. As
expected, b-HPVs were predominant in
both HIV patients and ICPs (84 and 76%,
respectively). Among a-HPVs, we did not
observe any difference between the
different species. Only b1-HPV36 and
b2-HPV17 types were significantly more
prevalent in HIV patients (27 and 25%,
respectively) than in ICPs (5 and 6%,
respectively). Although b-HPV types
were rarely detected, they seemed to be
more prevalent in HIV patients (14 vs.
4%; odds ratio 4, 95% confidence
interval 0.75–28.3), and only mucosal
a-HPV types were detected in these
patients.
We could not establish any signifi-
cant relation between the presence of
HPV DNA in eyebrow hair from HIV
patients and medical history of HPV
infection (cutaneous and/or genital warts
and cervical dysplasia), history of skin
cancer, CDC stages, HIV load (inferior
or superior to 40 copiesml–1), levels of
CD4 cells (inferior or superior to 500
CD4 cellsmm–3), and highly active
antiretroviral therapy (data not shown).
Although little is known about the
interaction between HPV and HIV (Kojic
and Cu-Uvin, 2007; van der Burg and
Palefsky, 2009), HIV-infected patients are
known to have an increased incidence of
HPV infection, HPV-associated cervical
or anal dysplasia, and cancer (Grulich
et al., 2007; Stier and Baranoski, 2008).
However, the prevalence of HPV DNA
in HIV patients in eyebrow hair has not
been assessed so far.
This study confirms the high overall
prevalence (76%) of HPV DNA in
eyebrow hair follicles from ICPs and
HIV patients (86%). Furthermore, the
chance of harboring HPV in eyebrow
hair was almost two times increased in
HIV patients compared with ICPs (odds
ratio 1.89, 95% confidence interval
0.66–5.49). These data thus confirm
that HPV DNA is widely distributed
among the population whatever its
immune status (Boxman et al., 1997;
Harwood et al., 2000; de Koning et al.,
2007, 2009; Hazard et al., 2007).
As expected, HIV patients showed
clinical history of mucosal HPV infec-
tion, and mucosal a-HPV DNA seemed
to be more prevalent in eyebrow hair.
There are no data on the cutaneous
prevalence of a-HPV in HIV patients,
but the high prevalence of a-HPV DNA
has been already shown in anogenital
mucosae (Drobacheff et al., 2003) and
in urine samples from HIV patients
without any correlation with the
CD4þ cell count or the HIV viral load
(Jong et al., 2009).
The prevalence and the distribution
of b-HPV types in the general popula-
tion without any skin lesion are largely
unknown. Recently, de Koning et al.
(2009) found a similar prevalence of
b-HPV infection in eyebrow hair from
both ICP and immunosuppressed
patients with HPV23 also as the most
prevalent type similar to this study.
In this study, as expected, b-HPVs
were predominant in both ICP and
HIV patients and the different species
showed a similar prevalence.
Despite similar prevalences, the
number of different HPV types was
significantly higher in HIV patients than
in ICPs. This was the result of a higher
prevalence of HPV 5, 8, 14, 15, 17, 22,
36, 38, and 47 in HIV patients (there
was at least a 10% difference in the
prevalence of these types compared
with the controls). Some of these HPV
types have been associated with skin
cancer in earlier studies (Struijk et al.,
2003; Feltkamp et al., 2008). Further-
more, this study confirms that immuno-
suppressed individuals are infected with
a greater number of HPV types than ICPs
of the same age group (Harwood et al.,
2000; de Koning et al., 2009).
We did not observe any correlation
between the presence of HPV DNA and
immune status of HIV patients. In pre-
vious studies, Hazard et al. (2007) and de
Koning et al. (2009) found that the overall
cutaneous HPV DNA prevalence was not
significantly associated with immunosup-
pressive treatment. However, the duration
of immunosuppression might be asso-
ciated with multiple b-HPV infection (de
Koning et al., 2009).
This study is however limited by the
fact that despite the detection of a
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Table 1. Rates of HPV DNA detection in eyebrow hairs
HPV DNA positivity1 ICP (n=50) HIV-P (n=63) ORs with 95% CIs
All genuses 76% (38) 86% (54) 1.89 (0.66–5.49)
Number of HPV types
1 22% (11) 13% (8) 0.52 (0.17–1.55)
2 22% (4) 14% (9) 1.92 (0.49–7.99)
42 46% (23) 59% (37) 1.67 (0.74–3.79)
Mean number±SD* 3±3.04 (n=50) 4.5±3.96 (n=63) P=0.03
a-HPV 4% (2) 14% (9) 4 (0.75–28.30)
b-HPV 76% (38) 84% (53) 1.67 (0.60–4.72)
b1-HPV 58% (29) 68% (43) 1.56 (0.67–3.63)
HPV5 24% (12) 34% (21) 1.58 (0.64–3.97)
HPV8 14% (7) 24% (15) 1.92 (0.65–5.79)
HPV12 14% (7) 19% (12) 1.45 (0.47–4.50)
HPV14 12% (6) 22% (14) 2.10 (0.67–6.75)
HPV19 4% (2) 13% (8) –2
HPV20 18% (9) 21% (13) 1.18 (0.42–3.38)
HPV21 8% (4) 5% (3) –2
HPV24 34% (17) 22% (14) 0.55 (0.22–1.38)
HPV25 0 3% (2) –2
HPV36* 10% (5) 27% (17) 3.33 (1.03–11.35)
HPV47 6% (3) 17.5 (11) 3.33 (0.79–16.04)
HPV93 6% (3) 6.4% (4) –2
b2-HPV 58% (29) 57% (36) 0.97 (0.43–2.19)
HPV9 8% (4) 14% (9) 1.92 (0.49–7.99)
HPV15 18% (9) 28% (18) 1.82 (0.68–4.98)
HPV17* 6% (3) 25% (16) 5.33 (1.33–24.78)
HPV22 6% (3) 16% (10) 2.96 (0.69–14.49)
HPV23 38% (19) 38% (24) 1 (0.44–2.32)
HPV37 6% (3) 1.6% (1) –2
HPV38 25% (14) 36.5% (23) 1.48 (0.62–3.57)
HPV80 4% (2) 11% (7) –2
b3-HPV 6% (3) 14% (9) 2.61 (0.60–13.01)
HPV49 2% (1) 0 –2
HPV75 2% (1) 9.5% (10) –2
HPV76 2% (1) 6.4% (4) –2
b4-HPV92 0 1.6% (1) –2
b5-HPV96 6% (3) 6.4% (4) –2
g-HPV 18% (9) 17% (11) 0.96 (0.33–2.83)
HPV4 6% (3) 5% (3) –2
HPV48 4% (2) 1.6% (1) –2
HPV50 8% (4) 13% (8) 1.67 (0.42–7.12)
HPV65 2% (1) 1.6% (1) –2
HPV95 0 1.6% (1) –2
Abbreviations: CI, confidence interval; HPV, human papillomavirus; ICP, immunocompetent patient; OR, odds ratio.
1Number of samples positive for HPV DNA.
2The number of cases was not large enough for statistical analysis.*Statistically significant at 5%.
Our assay (Gheit et al., 2007; Ruer et al., 2009) was designed to detect 19 mucosal high-risk and potential high-risk HPV types from genus a (16, 18, 26, 31,
33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 70, 73, and 82), 18 low-risk a-HPV types (6, 11, 28, 34, 40, 42, 43, 44, 54, 55, 57, 61, 67, 71, 72, 74, 81, 83,
and 84), 25 cutaneous HPV types from genus b (5, 8, 9, 12, 14, 15, 17, 19, 20, 21, 22, 23, 24, 25, 36, 37, 38, 47, 49, 75, 76, 80, 92, 93, and 96), and
6 cutaneous HPV types from genus g (4, 48, 50, 60, 65, and 95).
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broad spectrum of HPV DNA, we did
not evaluate its persistence, or the
transcriptional activity or the viral load.
In addition, we cannot exclude that
specific HPV types may be involved in
a subgroup of HIV patients, as the
power of this study may have been
too low to reach statistical significance.
In conclusion, this is the first study
on HPV DNA prevalence in healthy
skin of HIV patients. The high preva-
lence of HPV infection in humans,
together with the lack of specific HPV
types and any relation with the immune
status of HIV patients, raises the ques-
tion of how HPV could affect the
development of skin cancer in these
patients (Feltkamp et al., 2008).
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Atopic Dermatitis Lesions
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TO THE EDITOR
Staphylococcus aureus infection is a
known trigger for skin inflammation
and can modulate immune responses.
Atopic dermatitis (AD), a chronic in-
flammatory pruritic skin disease, affects
10–20% of children and 1–3% of adults
(De Benedetto et al., 2009). Owing to
the loss of skin integrity by scratching,
as well as decreased levels of antimi-
crobial peptides in comparison with
normal skin or other inflammatory
diseases such as psoriasis (Ong et al.,
2002; Leung, 2003), patients with AD
are particularly susceptible to staphylo-
coccal skin infections, which can
further worsen their skin disease
(Bieber, 2008). Studies have suggested
several underlying mechanisms for sta-
phylococcus-mediated inflammation,
which include production of inflamma-
tory cytokines following either direct
infection of keratinocytes or immune
cells by the bacteria, or indirectly byAbbreviations: AD, atopic dermatitis; LTA, lipoteichoic acid; SPA, staphylococcal protein A
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